Match!
Shumei Kato
University of California, San Diego
75Publications
12H-index
835Citations
Publications 79
Newest
Background Treatment outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC) remain dismal. There are unmet needs for understanding the biologic basis of this malignancy using novel next-generation sequencing technologies. Herein, we investigated the clinical utility of circulating tumor DNA (ctDNA) (the liquid biopsy) in this malignancy.
Source
Source
Author(s): Adashek, Jacob J; Kato, Shumei; Ferrara, Roberto; Lo Russo, Giuseppe; Kurzrock, Razelle | Abstract: There are currently seven approved immune checkpoint inhibitors (ICIs) for the treatment of various cancers. These drugs are associated with profound, durable responses in a subset of patients with advanced cancers. Unfortunately, in addition to individuals whose tumors show resistance, there is a minority subgroup treated with ICIs who demonstrate a paradoxical acceleration in the rate...
Source
Introduction/Background With advances in precision cancer medicine, personalized therapy approaches based on ‘omic’ analyses are being investigated. We present a patient with treatment refractory, metastatic ovarian cancer who achieved dramatic tumor reduction with a combination matched targeted therapy approach. Methodology Genomic aberrations were assessed using next-generation sequencing (NGS) from formalin-fixed paraffin embedded surgical tumor tissue (315 genes) (Foundation Medicine). Estro...
Source
#1In Sil Choi (UCSD: University of California, San Diego)H-Index: 1
#2Shumei Kato (UCSD: University of California, San Diego)H-Index: 12
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 9 authors...
Molecular profiling of circulating tumor DNA (ctDNA) is a promising non-invasive tool. Here, next-generation sequencing (NGS) of blood-derived ctDNA was performed in patients with advanced colorectal cancer (CRC). We investigated ctDNA-derived genomic alterations, including potential actionability, concordance with tissue NGS, and serial dynamics in 78 patients with CRC using a clinical-grade NGS assay that detects single nucleotide variants (54-73 genes) and selected copy number variants, fusio...
Source
#1Kristen K. Ciombor (Vandy: Vanderbilt University)H-Index: 5
#2Fang-Shu Ou (Mayo Clinic)H-Index: 8
Last.Tanios Bekaii-Saab (Mayo Clinic)H-Index: 37
view all 15 authors...
Background: Colorectal cancer (CRC) is the second leading cause of cancer death among men and women in the United States, and additional treatment strategies are needed for patients with advanced disease. Prospective therapeutic studies based on tissue-detected genomic targets such as ERBB2 (HER2), BRAF V600E, gene rearrangements/fusions, and microsatellite instability (MSI) have demonstrated clinical benefit for mCRC patients. Although correlative studies and/or retrospective case series utiliz...
Source
#1Taylor J. JensenH-Index: 5
#2Aaron GoodmanH-Index: 1
Last.Razelle KurzrockH-Index: 99
view all 16 authors...
Source
#1Kristina Mardinian (UCSD: University of California, San Diego)
#2Ryosuke Okamura (UCSD: University of California, San Diego)H-Index: 6
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 4 authors...
Author(s): Mardinian, Kristina; Okamura, Ryosuke; Kato, Shumei; Kurzrock, Razelle | Abstract: We investigated the impact of time interval, primary vs. metastatic biopsy site, variant allele fraction (VAF) and histology on concordance of KRAS alterations in tissue vs. circulating tumor DNA (ctDNA), and association of concordance with survival. Blood and tissue were evaluated by next-generation sequencing in 433 patients with diverse cancers. Altogether, 101 patients (23.3%) had KRAS alterations: ...
Source
#1Filip Janku (University of Texas MD Anderson Cancer Center)H-Index: 41
#2Eli L. Diamond (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 19
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 10 authors...
The BRAFV600E mutation and BRAF inhibitor responsiveness characterize ~50% of patients with the non-Langerhans cell histiocytosis (non-LCH) Erdheim-Chester disease (ECD). We interrogated the non-LCH molecular landscape (ECD, n=35; Rosai-Dorfman disease [RDD], n=3; mixed ECD/RDD, n=1) using BRAFV600E polymerase chain reaction and/or next-generation sequencing (tissue and cell-free DNA [cfDNA] of plasma and/or urine). Of 34 evaluable patients, 17 (50%) had the BRAFV600E mutation. Of 31 patients ev...
Source
#1Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 9
#2Shumei Kato (UCSD: University of California, San Diego)H-Index: 12
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 10 authors...
Advanced and metastatic squamous cell carcinomas (SCC) are common and difficult-to-treat malignancies. We assessed 75 immunotherapy-treated patients with SCC from a clinically annotated database of 2,651 patients, as well as 9,407 patients from a deidentified database for molecular features that might influence checkpoint blockade response. SCCs had higher tumor mutational burdens (TMB) than non-SCCs (P
1 CitationsSource
12345678